Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

Core Points - Beyond Air, Inc. has entered into a definitive agreement for the immediate exercise of certain outstanding common warrants to purchase up to 1,439,126 shares at a reduced exercise price of $2.21, expected to generate approximately $3.25 million in gross proceeds [1][3] - Laidlaw & Company (UK) Ltd. is acting as the exclusive placement agent for this offering, which includes the issuance of new unregistered warrants to purchase up to 719,561 shares at a purchase price of $0.0625 per New Warrant [2][4] - The offering is expected to close on or about September 9, 2025, and the net proceeds will be used to advance clinical and pre-clinical programs, as well as for operating expenses and working capital [3][4] Company Overview - Beyond Air is a commercial stage medical device and biopharmaceutical company focused on utilizing nitric oxide to improve the lives of patients with respiratory illnesses, neurological disorders, and solid tumors [6] - The company has received FDA approval for its LungFit® PH system, aimed at treating term and near-term neonates with hypoxic respiratory failure, and is advancing other LungFit systems in clinical trials for severe lung infections [6] - Beyond Air has partnered with The Hebrew University of Jerusalem to develop treatments for Autism Spectrum Disorder and is investigating ultra-high concentrations of nitric oxide for targeting solid tumors in pre-clinical settings [6]